Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Current Quarter	$-0.07	Next Quarter	$-0.08
Current Year	$-0.25	Next Year	$-0.3
QoQ Growth	-14.3%	YoY Growth	-20.0%
3Y EPS CAGR	-3.6%	Target Price	$5.69
Consensus	Buy	Upside	+629.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATOS	$0.78	+3.75%	595.33K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATOS	$0.78	+3.8%	595.33K
3
4
5
6

ATOS

ATOS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Atossa Therapeutics Inc. Data in Excel

Get Atossa Therapeutics Inc. Data in Excel